Andy Baxter

Andy has held senior technical and management positions in major pharmaceutical companies (Glaxo and Pfizer, where he was involved in the initial development of Sildenafil), emerging biotech companies (Chiroscience - Celltech) and, most recently, early-stage/small pharmaceutical companies (Arakis, Serentis and Altacor). Andy has acted as product development advisor to ATXA since spin-out in 2015 and continues to advise on all aspects of product development associated with the relevant technical work packages.

Andy has >28 years’ experience in the biotechnology and pharmaceutical industry, including in discovery and development from early research through to mid-stage clinical trials. His approach is to undertake extensive portfolio review during candidate selection, lead ID and optimisation (chemistry, strategy and screening), advice on IP innovation and diligence, to early development (pre-clinical, CMC, regulatory and early clinical) and product/pipeline due diligence.

Andy has a broad knowledge of most therapeutic areas and experience of many therapeutic targets. He is an inventor or co-inventor of over 60 patent applications. Andy has developed products as solid dose forms (including modified release), parental, topical, inhaled, intra-nasal, sub-lingual and transdermal patches. Andy has been successfully involved in both in-licensing and out-licensing projects and has managed collaborations between biotech and major pharmaceutical companies on a multidisciplinary level.